Klaria Pharma

Summary of the interim report

First quarter of 2026 The group in total

- Net sales 0.1 MSEK (9.0 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 4.9 MSEK (3.4 MSEK)

- Profit after tax amounted to -8.7 MSEK (-1.6 MSEK)

- Earnings per share for the quarter amounted to -0.04 SEK (-0.01 SEK)

- Cash flow from operating activities amounted to -0.1 MSEK (0.9 MSEK)

- Liquid assets on the balance sheet date amounted to 0.3 MSEK (1.5 MSEK)

- Group equity as of March 31 amounted to -20.6 MSEK (1.7 MSEK)

- Equity in the parent company as of March 31 amounted to 86.0 MSEK (75.4 MSEK)